Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model
/in International Publications, Newcastle Disease Virus, Pancreatic Cancer /von 2015-12-16 / Mol. Cancer 2015 Dec;14:210Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms‘ Tumor 1 in Patients with Advanced Colorectal Cancer
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2015-12-11 / Vaccines (Basel) 2015 Dec;3(4):1004-18A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2015-12-10 / Br. J. Cancer 2015 Dec;113(12):1666-76Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells
/in Dendritic Cells, HIV/AIDS, International Publications /von 2015-12-08 / J. Infect. Dis. 2016 May;213(9):1400-9Clinical research on dendritic cell vaccines to prevent postoperative recurrence and metastasis of liver cancer
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2015-12-08 / Genet. Mol. Res. 2015 Dec;14(4):16222-32HIV immunotherapy comes of age: implications for prevention, treatment and cure
/in Dendritic Cells, HIV/AIDS, International Publications /von 2015-12-02 / Expert Rev Clin Immunol 2016;12(2):91-4Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy
/in International Publications, Newcastle Disease Virus, NSCLC /von 2015-11-15 / Am J Cancer Res 2015;5(12):3612-23Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2015-11-15 / World J Gastrointest Oncol 2015 Nov;7(11):338-46Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2015-11-05 / Cancer 2016 Feb;122(3):367-77
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de